|[October 22, 2013]
BioAlliance Pharma launches its new website
PARIS --(Business Wire)--
BioAlliance Pharma launches its new website www.bioalliancepharma.com
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative
company dedicated to the development of orphan oncology products and to
supportive care products, today launches its new website www.bioalliancepharma.com.
BioAlliance Pharma offers a new public website for optimized access to
the Company's information, product portfolio and activities. The
interactive platform, thanks to a renewed and dynamic design, allows for
easy and efficient navigation through the site's various sections.
"The website is an essential tool to showcase the Company. We wished to
revisit it with a view to better reflect the strong Company dynamics
while facilitating access to key information for all our contacts,
especially our shareholders and the public at large, with an attractive
and user-friendly design," comments Judith Greciet, CEO of BioAlliance
The visual identity concept was developed by Limbus Studio, under the
leadership of Stefanos Athanassopoulos, Artistic Director.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on
esistance targeting and orphan products, BioAlliance Pharma conceives
and develops innovative products, for specialty markets especially in
the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005,
BioAlliance Pharma's ambition is to become a leading player in these
fields by coupling innovation to patient needs. The company's teams have
the key competencies required to identify, develop and register drugs in
Europe and the USA.
BioAlliance Pharma has developed an advanced product portfolio:
(oropharyngeal candidiasis in immunocompromised patients): Registered in
26 countries (EU, US, Korea), commercialized in Europe and in the US.
(Acyclovir Lauriad®) (labialis herpes): Registered in the US
and in 8 European countries, registration status in the other European
Fentanyl Lauriad® (chronic cancer pain):
Positive preliminary Phase I results
Orphan Oncology products
Transdrug™) (primary liver cancer): Phase III on going
(Clonidine Lauriad®) (mucositis): Phase II on going
(invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results,
financial condition, performance or achievements of BioAlliance Pharma
SA to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
BioAlliance Pharma SA is providing this communication as of this date
and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or
For a discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of BioAlliance
Pharma SA to differ from those contained in the forward-looking
statements, please refer to the Risk Factors ("Facteurs de Risque")
section of the 2012 Reference Document filed with the AMF on April 18,
2013, which is available on the AMF website (http://www.amf-france.org)
or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
[ Back To Technology News's Homepage ]